Indian Pharma Sector Expected To Grow 9%-11% in FY21-22: ICRA
IANS 04 January 2022
India's pharma sector is expected to grow at 9%-11% in FY21-22, rating agency ICRA said on Tuesday.
 
It attributed the growth to the improving demand for non-COVID products in addition to new product introductions, rupee depreciation and expanding market coverage.
 
"Going forward, sustenance of trend in doctor visits and elective surgeries given the news around the Omicron variant, and performance of new launches in addition to revenue growth momentum in the acute segment will remain key monitorables," ICRA said.
 
Further, pricing pressures and rising raw materials costs are expected to contract margins for the sector to 22.5% in FY21-22 and further to pre-COVID levels of 21%-22% in FY22-23, said Deepak Jotwani, assistant vice president and sector head, ICRA.
 
The outlook for the pharma sector remains 'Stable' led by healthy revenue growth and is seen remaining comfortable, despite higher capital expenditure and R&D (research & development) expenses given the robust cash levels.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.
Comments
Free Helpline
Legal Credit
Feedback